RayKnowChina Research Map
Shortlist

Not yet recruitingGliomaEarly phase 1

Registered title, quoted from ClinicalTrials.gov

Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma

An open trial on glioma, registered on ClinicalTrials.gov. Led by Beijing Tiantan Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06396481, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 4 years to Not stated; sex: all

    Registered eligibility fields

  2. Normal bone marrow reserve function and normal liver and kidney function (as evidenced by the following laboratory tests prior to initial Vγ9Vδ2 T cell therapy) :

    Inclusion criterion 5

  3. KPS score ≥70;

    Inclusion criterion 4

  4. Neutrophil absolute value ≥ 1,500/mm3;

    Inclusion criterion 6

    hemoglobin 10g/dL;

    Inclusion criterion 7

    Platelet count \> 100,000/mm3;

    Inclusion criterion 8

    Glutamic pyruvic transaminase/Glutamic oxalacetic transaminase \< 2.5 x ULN;

    Inclusion criterion 9

    Serum creatinine 1.5×ULN;

    Inclusion criterion 10

    Total bilirubin levels \< 1.5 x ULN.

    Inclusion criterion 11

  5. Women of reproductive age (15-49 years) must undergo a negative pregnancy test within 7 days before starting treatment and use contraception during the clinical trial period and within 3 months after the last cell transfusion;

    Inclusion criterion 16

    Pregnant and lactating women;

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06396481, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with clinically diagnosed malignant brain glioma in an important structural area (WHO Grade IV);
  • Patients with poor postoperative effect or ineffective guidelines for conventional treatment
  • Age ≥4 years old, male or female;
  • KPS score ≥70;
  • Normal bone marrow reserve function and normal liver and kidney function (as evidenced by the following laboratory tests prior to initial Vγ9Vδ2 T cell therapy) :
  • Neutrophil absolute value ≥ 1,500/mm3;
  • hemoglobin 10g/dL;
  • Platelet count \> 100,000/mm3;
  • Glutamic pyruvic transaminase/Glutamic oxalacetic transaminase \< 2.5 x ULN;
  • Serum creatinine 1.5×ULN;
  • Total bilirubin levels \< 1.5 x ULN.
  • No obvious genetic diseases;
  • Normal cardiac function, cardiac ejection index > 55%;
  • Suitable for implantation of Ommaya capsule in ventricle or cavity;
  • No bleeding and coagulation disorders;
  • Women of reproductive age (15-49 years) must undergo a negative pregnancy test within 7 days before starting treatment and use contraception during the clinical trial period and within 3 months after the last cell transfusion;
  • Sign the informed consent form.

Exclusion Criteria:

  • Pregnant and lactating women;
  • Organ failure;
  • Heart: Grade III and grade IV;
  • Liver: Level C of the Child-Turcotte liver function scale;
  • Kidney: renal failure and uremia stage;
  • Lungs: Symptoms of severe respiratory failure;
  • Brain: A person with a disorder of consciousness.
  • Patients with a history of organ transplantation;
  • Uncontrollable infectious disease or other serious illness, including but not limited to infection (such as HIV positive), congestive heart failure, unstable angina pectoris, arrhythmia, psychosis, or restrictive social environment or what the attending physician considers to be an unpredictable risk;
  • Patients with systemic autoimmune disease or immunodeficiency;
  • Patients with allergic constitution;
  • Use of systemic steroid drugs;
  • Have a chronic disease that requires the use of immune agents or hormone therapy;
  • Prior treatment with any other immune cell;
  • Have participated in other clinical trials within the past 30 days;
  • The researchers believe that other reasons are not suitable for clinical trials

Quoted from ClinicalTrials.gov, NCT06396481, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06396481, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06396481